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Résumé en
anglais
Rhenium-188 (Re) is a high energy beta-emitting radioisotope with a short 16.9 h
physical half-life, which has been shown to be a very attractive candidate for use in
therapeutic nuclear medicine. The high beta emission has an average energy of 784
keV and a maximum energy of 2.12 MeV, sufficient to penetrate and destroy targeted
abnormal tissues. In addition, the low-abundant gamma emission of 155 keV (15%) is
efficient for imaging and for dosimetric calculations. These key characteristics
identify Re as an important therapeutic radioisotope for routine clinical use.
Moreover, the highly reproducible on-demand availability of Re from the W/Re
generator system is an important feature and permits installation in hospital-based or
central radiopharmacies for cost-effective availability of no-carrier-added (NCA) Re.
Rhenium-188 and technetium-99 m exhibit similar chemical properties and represent
a "theranostic pair." Thus, preparation and targeting of Re agents for therapy is
similar to imaging agents prepared with Tc, the most commonly used diagnostic
radionuclide. Over the last three decades, radiopharmaceuticals based on Re-labeled
small molecules, including peptides, antibodies, Lipiodol and particulates have been
reported. The successful application of these Re-labeled therapeutic
radiopharmaceuticals has been reported in multiple early phase clinical trials for the
management of various primary tumors, bone metastasis, rheumatoid arthritis, and
endocoronary interventions. This article reviews the use of Re-radiopharmaceuticals
which have been investigated in patients for cancer treatment, demonstrating that Re
represents a cost effective alternative for routine clinical use in comparison to more
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